Compare NEXT & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEXT | NVAX |
|---|---|---|
| Founded | 2010 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.1B |
| IPO Year | N/A | 1995 |
| Metric | NEXT | NVAX |
|---|---|---|
| Price | $5.29 | $6.68 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 8 |
| Target Price | $9.00 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 3.6M | 3.2M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $1,064,651,000.00 |
| Revenue This Year | N/A | $58.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.25 |
| Revenue Growth | N/A | ★ 20.27 |
| 52 Week Low | $4.99 | $5.01 |
| 52 Week High | $12.12 | $11.55 |
| Indicator | NEXT | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 44.03 |
| Support Level | $5.31 | $6.36 |
| Resistance Level | $5.50 | $7.00 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 25.66 | 50.00 |
NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.